After seeing the price at which the Sanqing Anti-Cancer Drug had entered national medical insurance, every major domestic pharmaceutical company was stunned.
Raging fury erupted from the pharmaceutical executives' hearts.
"Is Wei Kang an idiot? How dare he set the price so low?"
"He's trying to force us all to our deaths."
"He wants to monopolize the anti-cancer drug market. What monstrous ambition—he's not even human!"
"He's too ruthless. I actually believed he would cooperate with us to develop the anti-cancer drug market together."
After their impotent rage came deep fear.
"It looks like the anti-cancer drug market is about to undergo a massive upheaval."
"Our companies need to transform as soon as possible."
"Give up on all generic anti-cancer drugs. At those prices, no one will buy them; as for our expensive self-developed drugs, there's even less hope."
"We can only do our best to expand overseas. We have to sell our anti-cancer drugs abroad."
"Pfizer Inc. is currently selling the Sanqing Anti-Cancer Drug in Europa and Eagle Country, but the vast Third World market is still entirely untapped. We still have plenty of room to grow."
"If we can't afford to provoke them, we can at least avoid them. Sanqing only has one anti-cancer drug for now, while our company has many types of medicine. We'll put all our resources into other fields and completely abandon the anti-cancer drug market."
"Fine, then. I refuse to believe Sanqing can roll out other new drugs so quickly."
The pharmaceutical executives hurried to coordinate with industry peers they knew, then revised their strategic plans. One after another, they withdrew from the anti-cancer drug market, pouring all their resources into other pharmaceutical fields and aggressively expanding overseas to seize foreign markets.
Of them all, Xinmei Group suffered the heaviest blow. Its newly